K Number
K242495
Manufacturer
Date Cleared
2025-04-29

(250 days)

Product Code
Regulation Number
868.5730
Reference & Predicate Devices
Predicate For
N/A
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

The LMA® Fastrach™ ETT Single Use is indicated for tracheal intubation through the LMA® Fastrach™.

The Stabiliser Rod is indicated for use during removal of the LMA® Fastrach™ and LMA® Fastrach™ Single Use after intubation to keep the LMA® Fastrach ™ ETT Single Use in place.

Device Description

The LMA® Fastrach™ ETT Single Use has been developed specifically for use with the LMA® Fastrach™. It is a straight, cuffed, wire-reinforced tube with a Murphy Eye and a standard 15mm connector.

The LMA® Fastrach™ ETT Single Use has a pilot balloon with a luer check valve and a unique, soft, moulded tip for atraumatic passage through the vocal cords. As a reference during intubation, the LMA® Fastrach™ ETT Single Use has depth markers to indicate the distance to the distal tip of the LMA™ airway. The LMA® Fastrach™ ETT Single Use is radiopaque along its full length and its tip is made out of a radio opaque material to enhance its visibility in x-rays.

Accessory device: The Stabiliser Rod Single Use is an accessory and it is indicated for use during removal of the reusable LMA® Fastrach™ and LMA® Fastrach™ Single Use after intubation to keep the Endotracheal Tube (ETT) in place.

AI/ML Overview

The provided 510(k) clearance letter and summary for the LMA Fastrach ETT SU is for a medical device (a tracheal tube), not a diagnostic AI/ML algorithm. Therefore, the information typically required for describing the acceptance criteria and study proving an AI/ML device meets those criteria (e.g., sample size for test/training sets, ground truth establishment, expert adjudication, MRMC studies) is not present in this document.

The document focuses on demonstrating substantial equivalence to a predicate device, as is standard for 510(k) submissions of traditional medical devices. This is achieved primarily through:

  • Comparison of features: Highlighting similarities in classification, product code, regulation number, size range, cuffed design, radiopacity, sterilization method, and eye (Murphy).
  • Performance data (bench testing): Verifying that the new device performs similarly to the predicate in terms of physical characteristics and durability.

Here's an analysis of the provided text in the context of your request for AI/ML device study details:


Acceptance Criteria and Device Performance (Based on provided text for a non-AI/ML device):

The "acceptance criteria" for this traditional medical device are primarily about demonstrating that it is substantially equivalent to a legally marketed predicate device and that it meets established engineering performance standards for tracheal tubes. The "device performance" is shown through bench testing.

Acceptance Criteria CategorySpecific Criteria (Inferred from text)Reported Device Performance
Substantial EquivalenceIntended Use, Technology, and Design are substantially similar to the predicate device. Minor differences are mitigated through testing."The subject device is substantially equivalent to the predicate device with respect to intended use, technology, and design." "The basic technological and operating principles are the same for both devices." "There are no significant differences that would affect safety and efficacy."
Physical PerformanceMeets performance characteristics critical to tracheal tubes (e.g., bond strength, kink resistance, cuff herniation, resistance to collapse, tracheal seal)."Testing performed included visual inspection, dimensional testing, bonding strength (main tube with boat tip, side arm, 15mm connector and cuff bonding), kink resistance, cuff herniation, resistance to collapse, tracheal seal testing." "The LMA Fastrach ETT SU passed all evaluations and tests."
BiocompatibilityMaterials comply with ISO 10993-1, ISO 18562-1, and FDA Guidance on Application of 10993-1."The device is biocompatible and meets the requires pertaining to biocompatibility per 10993-1, ISO 18562-1, the US FDA Guidance on Application of 10993-1." (Materials were changed to non-DEHP, and tested accordingly).
Sterility AssuranceSterilization method achieves a 10⁻⁶ SAL (Sterility Assurance Level)."Method of Sterilization: Ethylene Oxide 10⁻⁶ SAL" (Same as predicate).
MR SafetyDemonstrates MR Conditional status."MR Safety: MR Conditional" (Not declared on predicate; "Testing has been conducted" for the subject device).
Shelf-lifeDemonstrated shelf-life for the product."Shelf-life: 1 year" (Predicate had 2 years; "Testing has been conducted" for the subject device).
Packaging PerformancePackaging protects the device and maintains sterility in accordance with standards."Packaging performance testing was conducted." (Packaging materials differ from predicate, necessitating this testing).
Labeling ClarityIndications for Use and Contraindications are clear and aid safe use."Indication is not changing; a rewording was made for better readability." "Contraindications are not changing; a rewording was made for better readability. A statement has been added for the stabilizer rod, even though there are no known contraindications." (These indicate review and intended improvement in clarity, though the specific criteria for "readability" aren't quantified.)

Addressing your specific points for an AI/ML device study (based on the absence of this information in the document):

  1. A table of acceptance criteria and the reported device performance: As seen above, for a mechanical device, these are primarily about physical and material properties and substantial equivalence, not performance metrics like sensitivity/specificity for an AI/ML diagnostic.
  2. Sample size used for the test set and the data provenance: Not applicable. This document describes bench testing of a physical medical device. No "test set" of patient data is mentioned.
  3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable. Ground truth for a physical tube's performance is established by engineering and material science standards, not expert medical opinion on a data set.
  4. Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable. No adjudicators are mentioned as this is not a diagnostic device relying on interpretation.
  5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. This is a stand-alone physical medical device, not an AI-assisted diagnostic tool.
  6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. There is no algorithm.
  7. The type of ground truth used (expert concensus, pathology, outcomes data, etc): For a traditional mechanical device, "ground truth" is established by engineering standards, material specifications, and physical measurements (e.g., tensile strength, dimensional accuracy, sterilization efficacy).
  8. The sample size for the training set: Not applicable. This device is not developed using machine learning; therefore, there is no "training set."
  9. How the ground truth for the training set was established: Not applicable, as there is no training set for an AI/ML model.

Conclusion from the provided document:

The provided FDA 510(k) clearance letter and summary pertain to a traditional medical device (a tracheal tube), not a software as a medical device (SaMD) or an AI/ML-driven diagnostic tool. Therefore, the document does not contain the information relevant to AI/ML device performance studies, such as data provenance, expert adjudication, or MRMC studies. The "acceptance criteria" and "proof" in this context are based on a demonstration of substantial equivalence to a predicate device and successful completion of standard bench testing for physical and material properties.

FDA 510(k) Clearance Letter - LMA Fastrach ETT SU

Page 1

U.S. Food & Drug Administration
10903 New Hampshire Avenue Doc ID # 04017.07.05
Silver Spring, MD 20993
www.fda.gov

April 29, 2025

Teleflex Medical
Irma Govea
Regulatory Affairs Specialist
3015 Carrington Mills Blvd
Morrisville, North Carolina 27560

Re: K242495
Trade/Device Name: LMA Fastrach ETT SU
Regulation Number: 21 CFR 868.5730
Regulation Name: Tracheal Tube
Regulatory Class: Class II
Product Code: BTR
Dated: April 2, 2025
Received: April 2, 2025

Dear Irma Govea:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"

Page 2

K242495 - Irma Govea Page 2

(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic.

Page 3

K242495 - Irma Govea Page 3

See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Bradley Q. Quinn -S

Bradley Quinn
Assistant Director
DHT1C: Division of Anesthesia,
Respiratory, and Sleep Devices
OHT1: Office of Ophthalmic, Anesthesia,
Respiratory, ENT, and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

Page 4

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.

Indications for Use

Submission Number (if known)
K242495

Device Name
LMA Fastrach ETT SU

Indications for Use (Describe)

The LMA® Fastrach™ ETT Single Use is indicated for tracheal intubation through the LMA® Fastrach™.

The Stabiliser Rod is indicated for use during removal of the LMA® Fastrach™ and LMA® Fastrach™ Single Use after intubation to keep the LMA® Fastrach ™ ETT Single Use in place.

Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Page 5

510(k) Submission LMA Fastrach ETT SU

510(k) Summary - Page 1 of 4

A. Name, Address, Phone and Fax Number of Applicant

Teleflex Medical, Inc.
3015 Carrington Mill Blvd
Morrisville, NC 27560 USA
Phone: 1 919-361-3973

B. Contact Person

Irma Govea
Regulatory Affairs Specialist

C. Date Prepared

March 31, 2025

D. Device Name

Subject Device 1
Trade Name: LMA Fastrach™ ETT SU
Common Name: Endotracheal Tube
Product Code: BTR
Regulation Number: 21 CFR 868.5730
Classification Name: Tube, Tracheal (W/Wo Connector)
Classification: II
Classification Panel: Anesthesiology

E. Predicate Device

K051993 LMA Fastrach ETT SU

F. Device Description

The LMA® Fastrach™ ETT Single Use has been developed specifically for use with the LMA® Fastrach™. It is a straight, cuffed, wire-reinforced tube with a Murphy Eye and a standard 15mm connector.

The LMA® Fastrach™ ETT Single Use has a pilot balloon with a luer check valve and a unique, soft, moulded tip for atraumatic passage through the vocal cords. As a reference during intubation, the LMA® Fastrach™ ETT Single Use has depth markers to indicate the distance to the distal tip of the LMA™ airway. The LMA® Fastrach™ ETT Single Use is radiopaque along its full length and its tip is made out of a radio opaque material to enhance its visibility in x-rays.

Accessory device: The Stabiliser Rod Single Use is an accessory and it is indicated for use during removal of the reusable LMA® Fastrach™ and LMA® Fastrach™ Single Use after intubation to keep the Endotracheal Tube (ETT) in place.

G. Indications for Use

See Substantial Equivalence Table Below

Page 6

510(k) Submission LMA Fastrach ETT SU

510(k) Summary - Page 2 of 4

H. Contraindications

The LMA® Fastrach™ ETT Single Use should not be placed in patients eligible for procedures which involve the use of a laser beam or electrosurgical active electrode in the immediate area of the device.

There are no known contraindications associated with the Stabiliser Rod accessory device.

I. Substantial Equivalence

The subject device is substantially equivalent to the predicate device with respect to intended use, technology, and design. The differences between the predicate and the subject devices are minor and any risks have been mitigated through testing. The table below summarizes the differences between the subject and predicate device.

Table 1. Substantial Equivalence Comparative Table LMA Fastrach ETT SU

FeaturesTeleflex Medical LMA Fastrach ETT SUTeleflex Medical LMA Fastrach ETT SU (Predicate K051993)Comments
Classification NameTube, Tracheal (w/wo connector)SameSame
Product CodeBTRSameSame
Regulation Number868.5730SameSame
Indications for UseThe LMA® Fastrach™ ETT Single Use is indicated for tracheal intubation through the LMA® Fastrach™. The Stabiliser Rod is indicated for use during removal of the LMA® Fastrach™ and LMA® Fastrach™ Single Use after intubation to keep the LMA® Fastrach ™ ETT Single Use in place.The LMA Fastrach™ ETT SU is indicated for airway management by oral intubation on the trachea. Reinforced ETT may be used to reduce the potential for kinking whenever an unusual positioning of the head or neck is required following intubation.Indication is not changing; a rewording was made for better readability
Patient PopulationLMA® Fastrach™ ETT Single Use is intended for patients who require intubation through the Fastrach LMA to facilitate oxygenation and ventilation. Clinical judgement should be used in the selection of the appropriate device size for an individual patient.Not statedAlthough predicate device does not clearly state the patient population in the IFU, it remains the same for both products
ContraindicationsThe LMA® Fastrach™ ETT Single Use should not be placedLMA Fastrach ETT is contraindicated in proceduresContraindications are not

Page 7

510(k) Submission LMA Fastrach ETT SU

510(k) Summary - Page 3 of 4

FeaturesTeleflex Medical LMA Fastrach ETT SUTeleflex Medical LMA Fastrach ETT SU (Predicate K051993)Comments
in patients eligible for procedures which involve the use of a laser beam or electrosurgical active electrode in the immediate area of the device. There are no known contraindications associated with the LMA ® Fastrach™ Stabiliser Rod accessory device.which involve the use of a laser beam or electrosurgical active electrode in the immediate area of the device.changing; a rewording was made for better readability A statement has been added for the stabilizer rod, even though there are no known contraindications
Single UseYesSameYes
Size Range6.0 mm – 8.0 mmSameSame
CuffedYesSameSame
RadiopaqueYesSameSame
Connection to ventilation source15 mm connector Polyamide15 mm connector Polypropylene (PP)Materials have been tested per ISO 10993-1
Method of SterilizationEthylene Oxide 10⁻⁶ SALSameSame
BiocompatibilityMaterials have been tested per ISO 10993-1Materials biocompatibleMaterials have been tested per ISO 10993-1
Components & MaterialsMain tube – Non-DEHP Polyvinylchloride (PVC) reinforced with Stainless Steel Cuff – PVC Boat tip – PVC Inflation line – PVC Ink – Black Ink + Reducer Stabilizer rod - PVCMain tube – Polyvinylchloride (PVC) reinforced with Stainless Steel Cuff -PVC Boat tip – PVC Inflation line – PVC Ink – Black Ink Stabilizer rod - PVCMaterials were changed to non-DEHP
SterileYesSameSame
EyeMurphySameSame
GraduationsMultiple cm markingsSameSame
MR SafetyMR ConditionalNot declaredTesting has been conducted
Shelf-life1 year2 yearsTesting has been conducted

Page 8

510(k) Submission LMA Fastrach ETT SU

510(k) Summary - Page 4 of 4

| Packaging | Preformed pouch Packaging film – PET/EP 12/60 Tyvex – Uncoated Tyvex Paper 1073B | Blister tray Packaging film – Perfecseal 30652-EE (8 mil) nylon film Tyvex – PerfecSeal 2FS Tyvex heat seal coated with SBP 2000 | Packaging performance testing was conducted |

J. Comparison to the Predicate

The table above illustrates the similarities and differences between the subject and predicate device. The basic technological and operating principles are the same for both devices. Both the subject and predicate devices are for airway management. Both the subject and predicate devices are disposable, sterile, single patient use devices. The subject devices are substantially equivalent to the predicate device. There are no significant differences that would affect safety and efficacy.

K. Performance Data

The bench testing performed verifies that the performance of the subject device is substantially equivalent in terms of critical performance characteristics to the predicate device. These tests include:

  • Testing performed included visual inspection, dimensional testing, bonding strength (main tube with boat tip, side arm, 15mm connector and cuff bonding), kink resistance, cuff herniation, resistance to collapse, tracheal seal testing.

The testing performed verifies that the performance of the subject device is substantially equivalent in terms of critical performance characteristics to the predicate device.

The LMA Fastrach ETT SU passed all evaluations and tests. The device is biocompatible and meets the requires pertaining to biocompatibility per 10993-1, ISO 18562-1, the US FDA Guidance on Application of 10993-1.

L. Conclusion

The subject device has the same intended use and technological characteristics and construction as the predicate. Test results demonstrate that the subject device meets it's intended use. It is for these reasons that the subject device can be found substantially equivalent to the predicate devices.

§ 868.5730 Tracheal tube.

(a)
Identification. A tracheal tube is a device inserted into a patient's trachea via the nose or mouth and used to maintain an open airway.(b)
Classification. Class II (performance standards).